rhBMP-2体外诱导骨质疏松大鼠BMSCs成骨及VEGF表达的研究

目的:观察骨形态发生蛋白-2对骨质疏松时骨髓基质干细胞(BMSCs)体外成骨及成骨因子VEGF表达的影响,为骨质疏松证的防治提供新的方法。方法:将20只6月龄,体重(300±20) g雌性SD大鼠双侧卵巢切除,术后3个月利用双能X线骨密度仪测量大鼠全身骨密度并与术前比较,确保造模成功,并运用全骨髓贴壁法培养骨质疏松大鼠BMSCs,倒置相差显微镜下观察BMSCs形态。随机把骨质疏松大鼠BMSCs 第2代(p2)细胞分成实验组和对照组,分别加入完全培养基(含rhBMP-2)、成骨诱导液进行成骨诱导。2周后茜素红染色法检测各组细胞钙结节的形成,酶标仪测定碱性磷酸酶活性及RT-PCR法检测VEGF的表达量。结果:(1)大鼠全身骨密度:手术前后大鼠全身骨密度分别为(0.179±0.007),(0.158±0.006) g/cm²,差异有统计学意义(t=4.180,P<0.05).(2)茜素红染色:BMSCs(P2)成骨诱导2周后实验组染色效果明显强与对照组。(3)碱性磷酸酶活性:BMSCs(P2)成骨诱导2周后碱性磷酸酶活性实验组明显高于对照组,分别为(15.62±1.27),(8.62±0.93) μg/prot,差异有统计学意义(t=7.709,P<0.01).(4)BMSCs(P2)成骨诱导2周后VEGF表达:实验组明显高于对照组,分别为3.723±0.143,0.950±0.072,差异有统计学意义(t=29.462,P<0.01).结论:rhBMP-2能提高去卵巢骨质疏松大鼠BMSCs的体外成骨能力,可促进成骨因子VEGF的表达,调控VEGF的表达可能是骨形态发生蛋白-2参与骨代谢的机制之一。

Study on RhBMP-2 induced osteoporosis rat BMSCs in vitro osteogenesis and VEGF expression

Objective:To observe the impact of bone morphogenetic protein-2(rhBMP-2) on bone marrow stromal cells (BMSCs) osteogenesis in vitro and vascular endothelial growth factors (VEGF) expression in bone osteoporotic to prevent and treat the osteoporosis. Methods:Twenty 6-month-old female SD rats weighted(300±20)g underwent bilateral ovariectomized. At 3 months after operation,dual-energy X-ray absorptiometry was used to measure bone mineral density of rats,the values were compared with preoperative to ensure the model successfully,and the osteoporosis rats' BMSCs were cultured by bone marrow adherent cultured and the BMSCs morphology was observed under a phase contrast microscope upside down. The osteoporosis rats' BMSCs at the 2nd generation(p2) were randomly divided into experimental and control groups and were added complete medium (containing rhBMP-2) and osteogenic induced liquid,respectively. Two weeks later,the formation of cell calcium nodules were detected by Alizarin red staining method,alkaline phosphatase activity was measured by enzyme standard instrument and the expression of VEGF was detected by RT-PCT method. Results:(1)Whole body bone mineral density of rats before and after operation were (0.179±0.007),(0.158±0.006) g/cm²,there was statistically significant (t=4.180,P<0.05). (2)Alizarin red staining at 2 weeks after osteogenesis induced by BMSCs (P2) in the experimental group had more strong dyeing effect than the control group obviously. (3)Alkaline phosphatase activity at 2 weeks after osteogenesis induced by BMSCs (P2) of the experimental group (15.62±1.27) ug/gprot was significantly higher than that of the control group (8.62±0.93) ug/gprot,there was statistically significant (t=7.709,P<0.01). (4)The expression of VEGF at 2 weeks after osteogenesis induced by BMSCs(P2) of the experimental group 3.723±0.143 was significantly higher than that of the control group 0.950±0.072,there was statistically significant (t=29.462,P<0.01). Conclusion:RhBMP-2 can improve the in-vitro osteogenesis ability of ovary osteoporosis rat BMSCs,promote the VEGF expression of osteogenesis factor. Regulating the VEGF expression may be one of the mechanisms of BMP-2 to participate in bone metabolism.